Date Published:
16 August 2010 |
Scientists develop new drug treatment for malaria
Scientists at the University of Liverpool and the Liverpool School of Tropical Medicine have produced a new antimalarial drug that is more chemically stable in the body than current malaria treatments.
As part of the £1.5 million project, researchers are now testing the drug to determine how the treatment could progress to clinical trials. The drug is made from simple organic molecules and will be cheaper to mass produce compared to existing therapies.
Malaria is the world’s most deadly parasitic infection, resulting in nearly one million deaths a year. The team at Liverpool have created a synthetic drug based on the chemical structure of artemisinin, an extract of a Chinese herb commonly used in malaria treatment. The new drug, which can be taken orally, is more potent than naturally derived artemisinin.
Artemisinin is known to interact with a substance inside parasite-infected red blood cells, causing a chain of events that destroys malaria. The treatment, however, is difficult to mass produce and can be chemically unstable in the body. Scientists have now found a way of creating the most reactive part of artemisinin synthetically and fusing it with a cage-like structure made of organic molecules to make the drug more chemically stable. The stability of the chemical structure in the body makes the drug last longer, reducing the chance of the parasite reappearing.
Professor Paul O’Neill, from the University’s Department of Chemistry, explained:
“ Malaria affects the world’s poorest countries and hospitals are unable to afford expensive treatments. The problem with current artemisinin-based therapies is their limited availability, poor oral absorption and high cost. We have created a new drug that is easily absorbed by the body, chemically stable and highly potent. It is made from very simple organic materials and therefore will be more cost-effective to mass produce than current therapies.”
News
is included on the IvyRose website to inform visitors about current health
issues,
but not to endorse
any particular
view or activity. Any views expressed iin the article above
are not necessarily those of IvyRose Ltd.. Material in this news item was released
by
the source listed below
on 16 August 2010 and
may have been edited (e.g. in style, length, and/or for
ease
of understanding
by our international readers) for inclusion here. For further information,
please visit their website.
|
